NEXTECH INVEST LTD
Q3 2022 Form 13-F

ZURICH
CIK 0001911010 · CRD 322629 · Exempt reporting adviser
$309.6M Reported Value Total
Exempt Reporting Adviser
Source: Form ADV filed 2026-03-27
Reported value
$309.6M
Quarter over quarter
+4.2%
Holdings
14
Top-10 concentration
93.0%

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Marco Weibel
Chief Financial Officer

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2022 13F record

Q3 2022 13F filing summary

Q3 2022 Form 13F portfolio summary
Period of report September 30, 2022
Filed November 14, 2022
Form 13F-HR
Reported value $309.6M
Positions 14
Change in reported value +4.4%
New positions 0
Exited positions 0
Position turnover 0.0%
Top-10 concentration 93.0%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q4 2024 13F
Filed Feb 14, 2025
15 $616.4M
Q3 2024 13F
Filed Nov 14, 2024
15 $712.3M
Q2 2024 13F
Filed Aug 14, 2024
13 $594.5M
Q1 2024 13F
Filed May 15, 2024
12 $630.8M
Q4 2023 13F
Filed Feb 14, 2024
11 $536.8M
Q3 2023 13F
Filed Nov 14, 2023
14 $330.0M
Q2 2023 13F
Filed Aug 14, 2023
13 $294.2M
Q1 2023 13F
Filed May 12, 2023
12 $239.6M
Q4 2022 13F
Filed Feb 14, 2023
14 $251.4M
Q3 2022 13F
Filed Nov 14, 2022
14 $309.6M
Q2 2022 13F
Filed Aug 1, 2022
14 $296.5M
Q1 2022 13F
Filed May 16, 2022
14 $350.3M
Q4 2021 13F
Filed Feb 14, 2022
11 $379.6M

Top 14 holdings · Q3 2022

Largest Q3 2022 13F positions by reported value
# Holding Reported value % of portfolio
1 RVMD REVOLUTION MEDICINES INC $82.6M 26.68%
2 EQRX EQRX INC $64.9M 20.95%
3 KNTE KINNATE BIOPHARMA INC $31.8M 10.27%
4 TYRA TYRA BIOSCIENCES INC $22.1M 7.15%
5 MRTX MIRATI THERAPEUTICS INC $18.4M 5.95%
6 PMVP PMV PHARMACEUTICALS INC $16.5M 5.33%
7 CGEM CULLINAN ONCOLOGY INC $15.7M 5.06%
8 ARVN ARVINAS INC $12.8M 4.13%
9 BPMC BLUEPRINT MEDICINES CORP $12.4M 4.01%
10 RLAY RELAY THERAPEUTICS INC $10.6M 3.44%
11 SPRY SILVERBACK THERAPEUTICS INC $10.1M 3.26%
12 KRON KRONOS BIO INC $4.9M 1.57%
13 THRX THESEUS PHARMACEUTICALS INC $3.5M 1.15%
14 CCCC C4 THERAPEUTICS INC $3.3M 1.06%

Values as reported on the Q3 2022 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings